Roche Pharmaceutical Development and Sales Overview

Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator Indication Phase/study # of patients Design Primary endpoint Status CT Identifier 1L ER+ metastatic breast cancer (mBC) Phase III persevERA Breast Cancer N=978 ARM A: Giredestrant plus palbociclib ☐ ARM B: Letrozole plus palbociclib Progression-free survival FPI Q4 2020 ER-Estrogen receptor; HER2-Human Epidermal growth factor Receptor NCT04546009 Adjuvant ER+ breast cancer (BC) Phase III lidERA Breast Cancer N=4,100 ◉ ARM A: Giredestrant monotherapy ARM B: Tamoxifen or aromatase inhibitor Invasive disease-free survival FPI Q3 2021 NCT04961996 Roche 114 Oncology

View entire presentation